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Abstract: Following initial standard chemotherapy (platinum/taxol), more than 75% of those patients with advanced stage epithelial 
ovarian cancer (EOC) experience a recurrence. There are currently no accurate prognostic tests that, at the time of the diagnosis/surgery, 
can identify those patients with advanced stage EOC who will respond to chemotherapy. Using a novel mathematical theory, we have 
developed three prognostic biomarker models (complex mathematical functions) that—based on a global gene expression analysis 
of tumor tissue collected during surgery and prior to the commencement of chemotherapy—can identify with a high accuracy those 
patients with advanced stage EOC who will respond to the standard chemotherapy [long-term survivors (.7 yrs)] and those who will 
not do so [short-term survivors (,3 yrs)]. Our three prognostic biomarker models were developed with 34 subjects and validated with 
20 unknown (new and different) subjects. Both the overall biomarker model sensitivity and specificity ranged from 95.83% to 100.00%. 
The 12 most significant genes identified, which are also the input variables to the three mathematical functions, constitute three distinct 
gene networks with the following functions: 1) production of cytoskeletal components, 2) cell proliferation, and 3) cell energy produc-
tion. The first gene network is directly associated with the mechanism of action of anti-tubulin chemotherapeutic agents, such as taxanes 
and epothilones. This could have a significant impact in the discovery of new, more effective pharmacological treatments that may 
significantly extend the survival of patients with advanced stage EOC.
Keywords: ovarian cancer, biomarkers, mathematical models, prognostic biomarker models, treatment response, survival, global gene 
expression analysisNikas et al
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal 
gynecological malignancy in the U.S.A. Each year, 
approximately  21,880  women  are  diagnosed  with 
EOC, and approximately 13,850 women succumb to 
the disease.1 Over 60% of the patients with EOC are 
diagnosed at an advanced stage, ie, III or IV [Inter-
national  Federation  of  Gynecology  and  Obstetrics 
(FIGO) staging system]1,2 due to the lack of early 
symptoms.  The  five-year  survival  rate  for  those 
patients with stage III or IV EOC is less than 30%.2 
Maximal peritoneal cytoreduction surgery followed 
by  platinum  and  taxol  chemotherapy  constitutes 
the current standard care for those patients with an 
advanced stage of EOC.3,4 Approximately, 70%–80% 
of the patients with advanced-stage EOC, initially, 
respond favorably to the platinum/taxol chemother-
apy, but more than 75% of them soon experience a 
recurrence.5,6  Clearly,  prognostic  tests  that  could 
accurately  prognose,  at  the  time  of  the  diagnosis/
surgery,  the  response  to  the  standard  treatment  of 
care and, therefore, the survival of those patients are 
in great need. Such prognostic tests would be invalu-
able in: 1) providing the physicians with the ability 
to  identify  responders  from  non-responders  at  the 
outset (immediately after surgery), 2) providing alter-
native therapies to non-responders of platinum/taxol, 
and 3) helping pharmaceutical companies to test and 
develop new analogs of chemotherapeutic agents that 
may be more effective for the non-responders.
In this study, by analyzing the global gene expres-
sion data of the tumor tissue obtained during surgery 
(and, therefore, prior to the administration of chemo-
therapy) from 54 patients with advanced-stage EOC 
(III–IV), we developed three prognostic biomarker 
models that were able to identify with a high accu-
racy (overall sensitivity: 95.83%–100.00% and over-
all specificity: 95.83%–100.00%) both the responders 
[long-term survivors (LTS)] and the non-responders 
[short-term  survivors  (STS)]  to  the  platinum/taxol 
chemotherapy.  We  developed  all  three  prognostic 
biomarker  models  using  34  patients  [14  R/LTS 
(responders/long-term  survivors)  and  20  NR/STS 
(non-responders/short-term survivors)], and we vali-
dated  all  three  of  them  with  20  unknown  patients 
[10 R/LTS and 10 NR/STS] that were new and dif-
ferent from those 34 used in the development of the 
models.
Each of our three prognostic biomarker models is a 
complex mathematical function of a number of genes. 
Five genes are common input variables to all three prog-
nostic biomarker models, and they are deemed highly 
significant in the process of the response to treatment 
and, thus, to the survival of patients with stage III or 
IV EOC. Of those five genes, one is directly associated 
with the mechanism of action of taxol—one of the two 
anti-cancer agents of the standard chemotherapy—and 
one gene is indirectly associated with the mechanism 
of action of taxol. Moreover, from the remaining most 
significant genes, one is also indirectly associated with 
the mechanism of action of taxol.
Materials and Methods
Data acquisition and clinical sample 
information
We  used  the  raw  intensity  microarray  data  (CEL 
files) by Berchuck et al7 posted at the Duke Insti-
tute for Genome Sciences and Policy [Clinical can-
cer  research  11,  3686–3696  (2005)→ ( http://data.
genome.duke.edu/clinicalcancerresearch.php)].
Briefly, according to Berchuck et al7 tumor tissue 
was harvested from 54 EOC patients with stages III 
and IV during surgery (48 with stage III and 6 with 
stage IV) and prior to the commencement of platinum/
taxol chemotherapy. Total RNA was extracted from 
each tumor tissue sample and was analyzed for global 
gene expression using the GeneChip array U133A by 
Affymetrix. Following platinum/taxol chemotherapy, 
all 54 patients were followed for a period greater than 
seven years. Thirty patients survived for a period less 
than  3  years  [NR/STS  (non-responders/short-term 
survivors)–(median  survival  =  17.5  months)],  and 
24 patients survived for a period greater than 7 years 
[R/LTS  (responders/long-term  survivors)–(median 
survival = 107.5 months)]. None of the 30 NR/STS 
subjects died of causes other than EOC. At the time of 
the diagnosis, there was no significant age difference 
between the NR/STS subjects (median age = 59 yrs) 
and the R/LTS subjects (median age = 62 yrs). All 6 
patients with stage IV EOC turned out to be NR/STS 
subjects. For more demographic and clinical details, 
please see the study by Berchuck et al.7
Discovery and validation studies
Of the 54 patients, we randomly selected 34 of them 
(14  R/LTS  and  20  NR/STS)  for  the  development Prognosis of treatment response and survival in ovarian cancer
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and  training  of  the  prognostic  biomarker  models. 
The remaining 20 subjects (10 R/LTS and 10 NR/
STS) constituted the unknown subjects with which 
all  prognostic  biomarker  models  were  tested. This 
validation  method  provided  us  with  the  means  to 
test our prognostic biomarker models with 20 new 
and real unknowns that were different from the sub-
jects used for—and, therefore, completely extraneous 
to—the development and training of the models.
Statistical methods
We processed the original raw intensity data (CEL 
files)  using  the  MAS5  algorithm  (510  K  FDA 
approved). The Affymetrix U133A chip has 22,283 
probe sets that can interrogate an equal number of 
transcripts.
In order to reduce the dimensionality of the data 
and zero in on those variables (transcripts) that are 
most significant in the process of treatment-response/
survival in the case of EOC patients, we applied our 
bioinformatic methods that we have developed, pre-
sented, and explained in a great detail in our previous 
studies.8–10 Briefly, we performed ROC curve analysis 
on the entire data matrix, ie, on all variables (22,283 
transcripts × 54 subjects) in order to assess the dis-
criminating capability of all variables with respect to 
our two groups, namely, R/LTS and NR/STS. In the 
final round, we selected only those variables with an 
AUC $ 0.80. Eighty four variables (transcripts) ful-
filled this criterion, and they constituted the final pool 
of the most significant variables.
generation of super variables
From the aforementioned 84 most significant vari-
ables, 13 became the input variables to the three com-
plex mathematical functions (F1, F2, and F3), which 
we were able to generate, and which we term—and 
henceforward  refer  to  as—super  variables.  Those 
three super variables (complex mathematical func-
tions)  are  the  final  prognostic  biomarker  models. 
We  should  point  out  here  that  several  other  super 
variables were generated employing the remaining of 
the aforementioned 84 most significant variables, but, 
following final assessment, they proved to be not as 
robust as the F1, F2, or F3, and they are consequently 
not presented here. The F1 super variable is a function 
of 7 of the 13 aforementioned significant variables/
transcripts, and all of those 7 transcripts correspond 
to 7 different genes. The F1 super variable, therefore, 
is a function of the following 7 genes:
F1 = f {ACTB, EED, LYPLA2, MED13L,  
    OSBPL8, PKP4, TUBA3C}  (1.1)
The F2 super variable is a function of 10 of the 
13  aforementioned  significant  variables/transcripts, 
and 8 of those 10 transcripts correspond to 8 different 
genes. The remaining two transcripts correspond to 
the same gene, namely ACTB. Statistically, those two 
variables/transcripts were determined to be the same 
(P . 0.90), and that accords with the fact that two 
different probe sets are probing the same gene. The F2 
super variable, therefore, is a function of 10 different 
transcripts, or 9 different genes.
F2 = f {ACTB, EED, HLCS, LYPLA2, 
    MED13L, NDUFB1, SSR1, TUBA3C,  
    USP5}  (1.2)
The F3 super variable is a function of 8 of the 13 
aforementioned significant variables/transcripts, and 
6  of  those  8  transcripts  correspond  to  6  different 
genes. The remaining two transcripts, which are the 
same as the two mentioned in connection with the F2 
super variable, correspond to the same gene, namely 
ACTB, as was the case with the F2 super variable. 
The F3 super variable, therefore, is a function of 8 dif-
ferent transcripts, or 7 different genes.
F3 = f {ACTB, CDC42, EED, HLCS,  
    LYPLA2, MED13L, TUBA3C}  (1.3)
The three super variables constitute three differ-
ent and independent complex mathematical functions 
(Supplementary  Data),  and,  therefore,  three  differ-
ent and independent prognostic biomarker models of 
treatment-response/survival of patients with stage III 
or IV EOC. As can be seen from Equations (1.1), 
(1.2), and (1.3), five genes are common to all three 
super variables and are, thus, very important to the 
process of interest, ie, treatment-response/survival of 
patients with stage III or IV EOC. Those five genes 
are: ACTB, EED, LYPLA2, MED13L, and TUBA3C. 
Of those, the genes TUBA3C and ACTB are directly 
and indirectly (respectively) associated with the mech-
anism  of  action  of  taxol.  Furthermore,  the  gene   Nikas et al
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CDC42, a constituent variable of the F3 super variable, 
is also indirectly associated with the mechanism of 
action of taxol. As can also be seen from Equations 
(1.1), (1.2), and (1.3), the three super variables are 
collectively composed of 12 different genes (or 13 
different transcripts), all of which are listed in Table 1, 
along with their name, relative differential expres-
sion, and other properties.
Computer programs
Computer  programs  were  written  using  MATLAB 
R2010b by The MathWorks, Inc., Natick, MA, USA.
Results
Discovery study
As was mentioned earlier, from the total number of 
54 subjects (24 R/LTS and 30 NR/STS) used in this 
study, we randomly selected 34 subjects (14 R/LTS 
and 20 NR/STS) for the development and training 
of  the  three  prognostic  biomarker  models  (F1,  F2, 
and  F3);  and  we  will  henceforward  refer  to  those 
34  subjects  as  the  34  original  subjects.  After  the 
development  of  those  three  prognostic  biomarker 
models, we assessed their prognostic accuracy using 
the aforementioned 34 original subjects, which were 
employed for their development. This constitutes an 
important first step in the assessment of a prognostic 
(or a diagnostic) test.
The cut-off score of the F1 prognostic biomarker 
model, as well as those of the other two models, was 
determined by taking into account the results of the 
following two analyses: 1) calculation of the optimal 
point  on  the  ROC  curve  based  on  the  34  scores 
of  the  34  original  subjects  used  in  the  discovery 
study [optimal point is defined as the point with the 
highest sensitivity and the lowest false positive rate 
(1-specificity)] and 2) calculation of the 99.99% con-
fidence intervals for the mean F1 scores of the two 
groups  (R/LTS  and  NR/STS)  and  their  respective 
standard deviations. Based on that, the cut-off score of 
the F1 model was determined to be 21.388. If a subject 
has an F1 score less than 21.388, then that subject is 
classified as an R/LTS; otherwise, that subject is clas-
sified as an NR/STS. As can be seen from Figure 1A, 
the F1 model correctly identified all (14/14) R/LTS 
subjects and 19/20 NR/STS subjects. In terms of treat-
ment response, since we would like to identify those 
subjects  that  will  respond  to  the  platinum/taxol 
chemotherapy, our target group is the R/LTS and our 
reference group is the NR/STS. Therefore, for the dis-
covery study, insofar as response to treatment is con-
cerned, the F1 model exhibited a sensitivity = 1.000 
and a specificity = 19/20 = 0.950. In the case of sur-
vival, given that we are interested in identifying the 
subjects that will be short-term survivors, our target 
group is the NR/STS and our reference group is the   
R/LTS.  With  regard  to  survival,  therefore,  for 
the  discovery  study,  the  F1  model  exhibited  a 
sensitivity = 0.950 and a specificity = 1.000. Both 
Figure 1A and Tables 2A and 2B show all pertinent 
statistical results of the F1 prognostic biomarker model 
in connection with the discovery study in great detail.
The cut-off score of the F2 prognostic biomarker 
model was determined to be 14.259. If a subject has 
an F2 score less than 14.259, then that subject is clas-
sified as an R/LTS; otherwise, that subject is classi-
fied as an NR/STS. As can be seen from Figure 1B, 
the F2 model correctly identified 13/14 R/LTS sub-
jects and all (20/20) NR/STS subjects. In connection 
with treatment response, therefore, and with regard 
to  the  discovery  study,  the  F2  model  exhibited  a 
sensitivity = 13/14 = 0.929 and a specificity = 1.000; 
whereas in connection with survival, its sensitivity 
and  specificity  were  1.000  and  0.929,  respectively. 
Figure 1B and Tables 2A and 2B show all pertinent 
statistical results of the F2 prognostic biomarker model 
in connection with the discovery study in great detail.
Regarding the F3 prognostic biomarker model, the 
cut-off score was determined to be 14.694, signifying 
that a score less than 14.694 belongs to an R/LTS sub-
ject, whereas a score greater than 14.694 belongs to an 
NR/STS subject. As can be seen from Figure 1B, the 
F3 model correctly identified all (14/14) R/LTS sub-
jects and 19/20 NR/STS subjects. For the discovery 
study, therefore, with regard to treatment response, 
the sensitivity and specificity of the F3 model were 
1.000  and  0.950,  respectively;  with  regard  to  sur-
vival, its sensitivity and specificity were 0.950 and 
1.000, respectively. Figure 1B and Tables 2A and 2B 
show all pertinent statistical results of the F3 prognos-
tic biomarker model in connection with the discovery 
study in great detail.
Figure 2 shows the 3D scatter plot of the F1vs. F2 
vs. F3 scores of all 34 original subjects, providing, Prognosis of treatment response and survival in ovarian cancer
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thus, a visual depiction of the prognostic accuracy of 
all three models with respect to the discovery study.
Validation study
As  was  mentioned  earlier,  from  the  total  number 
of 54 subjects (24 R/LTS and 30 NR/STS) used in 
this study, we had randomly segregated 20 subjects 
(10 R/LTS and 10 NR/STS) for the sole and express 
purpose  of  testing  our  three  prognostic  biomarker 
models. Those 20 unknown subjects were completely 
extraneous to all three models, that is to say they 
were new and different from the original 34 subjects, 
and they had never before been encountered by any 
of the three models. This constitutes the most impor-
tant test in the assessment of a prognostic (or diag-
nostic) test.
As  can  be  seen  from  Figures  3A  and  3B  and 
Table  2C,  all  three  prognostic  biomarker  models 
correctly prognosed all of the 20 unknown subjects. 
More  specifically,  all  10  R/LTS  subjects  had  F1, 
F2, and F3 scores that were less than the respective 
cut-off scores (21.388, 14.259, 14.694); whereas all 
10 NR/STS subjects had F1, F2, and F3 scores that 
were greater than the respective aforementioned cut-
off scores. Therefore, with regard to both response 
to treatment and survival, and in connection with the 
validation study, both the sensitivity and the speci-
ficity of all three prognostic biomarker models were 
1.000. Figure 4 shows the 3D scatter plot of the F1 vs. 
F2 vs. F3 scores of all 20 unknown subjects, providing, 
thus, a visual depiction of the prognostic accuracy of 
all three models with respect to the validation study.
Table 2D, in addition to other pertinent statisti-
cal results of our three prognostic biomarker models, 
shows the observed mean F1, F2, and F3 scores of the 
two groups (R/LTS and NR/STS) of the 20 unknown 
subjects. As can be seen, all six of those group mean 
scores, as observed in the validation study with the 20 
unknown subjects, fall within the 99.99% confidence 
intervals of the respective group mean scores as pre-
dicted in the discovery study (Table 2A).
Overall prognostic biomarker model 
performance
If we combined the discovery study results with those 
of the validation study, then the overall performance 
of our three prognostic biomarker models would be as 
follows. With regard to treatment response, both the 
F1 and F3 exhibited a sensitivity = 1.000 (24/24 R/LTS 
subjects) and a specificity = 0.967 (29/30 NR/STS 
subjects); whereas the F2 exhibited a sensitivity = 0.958 
(23/24  R/LTS  subjects)  and  a  specificity  =  1.000 
(30/30  NR/STS  subjects).  With  regard  to  survival, 
both the F1 and F3 exhibited a sensitivity = 0.967 
(29/30 NR/STS subjects) and a specificity = 1.000 
(24/24 R/LTS subjects); whereas the F2 exhibited a 
sensitivity = 1.000 (30/30 NR/STS subjects) and a 
specificity = 0.958 (23/24 R/LTS subjects).
gene networks
In connection with the 12 constituent genes of all 
three  super  variables,  we  conducted  an  Ingenuity 
Pathways Analysis (IPA) search. We sought to ascer-
tain all that was known about those 12 genes pertain-
ing to their function/process, their known interactions 
with other genes, and their known interactions with 
drugs, chemicals, and/or hormones as derived from 
the findings of scientific, peer-reviewed studies. The 
IPA results are listed in Table 1, along with the direc-
tion of the statistically significant differential expres-
sion (over-expression or under-expression) of those 
12 genes in the NR/STS group relative to that of the 
R/LTS group.
The aforementioned 12 genes can be categorized 
into three general groups: 1) genes that regulate the 
expression of cytostructural proteins, 2) genes that 
regulate cell proliferation, and 3) genes that regulate 
metabolism.
The  genes ACTB,  TUBA3C,  and  CDC42  have 
functions that pertain to the cytoskeleton, and as such, 
they compose the first group.
Cancer proliferation and metastasis relies on cyto-
structural materials, ie, cytoskeletal proteins, such as 
microfilaments (actin) and microtubules.11,12 The first 
two genes promote the expression of actin and micro-
tubules, respectively. CDC42 promotes the polymer-
ization of actin into microfilaments13,14; reorganization 
of the actin cytoskeleton15; and cell formation, growth, 
andspreading.16,17 There is also evidence that CDC42 
can regulate the polarization of both the actin and the 
microtubule cytoskeleton.13,18 In our study all three of 
the aforementioned cytostructural genes were signifi-
cantly over-expressed in the NR/STS group relative 
to the R/LTS group.Nikas et al
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The following genes, whose function pertains to 
cell  proliferation  in  general,  compose  the  second 
group: MED13L, SSR1, PKP4, EED, and USP5.
The MED13L protein (also known as, among other 
names, THRAP2, TRAP240L, and KIAA1025) is a 
member of the Mediator complex, a group of about 
30 transcriptional co-activators that play various reg-
ulatory roles in the induction of RNA polymerase II 
transcription.19 Compositional differences may account 
for different functions among the Mediator proteins; 
for instance some promote transcription, whereas oth-
ers act as transcriptional repressors.19,20 A number of 
those Mediator proteins are novel, and, consequently, 
their exact function is not known, including that of 
MED13L.21  Regarding  specifically  the  MED13L 
gene,  it  has  been  observed  that  over-expression  of 
the TP53 gene (p53) in human colon carcinoma cell 
lines  relative  to  controls  suppresses  the  expression 
of  MED13L  (KIAA1025).22  That  could  very  well 
explain our finding that the MED13L gene was sig-
nificantly under-expressed in the NR/STS group rela-
tive to the R/LTS group by affirming the existence of a 
more aggressive EOC cancer in the case of the former 
group in comparison with the latter one.
SSR1  is  an  ER  (endoplasmic  reticulum)  recep-
tor part of the translocon-associated protein (TRAP) 
complex. The function of the TRAP complex remains 
unclear,23,24 and that is even more so in the case of 
disease, such as cancer. In general, it is thought that 
the TRAP complex proteins are involved in protein 
translocation from the ER and in protein processing 
(folding,  sorting,  and  degradation)  in  the  ER. The 
SSR1, more specifically, has been hypothesized to be 
involved in the unfolded protein response (UPR) in 
the ER, ie, protein degradation, when there is a large 
accumulation of abnormal proteins.25 In our study, 
the SSR1 gene was significantly under-expressed in 
the NR/STS group relative to the R/LTS group.
The PKP4 protein (aka p0071) belongs to the fam-
ily of arm-repeat proteins,26 which are involved in 
cell adhesion.27 There is little known about both the 
structural and the functional role of the PKP4 pro-
tein.27 According to the results of our analysis, the 
PKP4 gene was significantly under-expressed in the 
NR/STS group relative to the R/LTS group, and that 
accords with the observation that metastatic cancer 
cells rely on greater cell mobility and, thus, lower cell 
adhesion.Nikas et al
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Figure 1.  (A) Scatter plot and bar graph of all 34 original subjects [14 R/LTS (green) and 20 NR/STS (purple)] used in the Discovery Study in connec-
tion with the F1 prognostic biomarker model. As can be seen, all 14 r/LTS subjects (green color) had F1 scores less than the determined cut-off score of 
21.4, and, therefore, they were all identified correctly [for treatment response: sensitivity = 1.000; for survival: specificity = 1.000]. regarding the Nr/STS 
group (purple color), 19/20 had F1 scores greater than the determined cut-off score of 21.4, and, therefore, 19/20 were identified correctly [for treatment 
response: specificity = 19/20 = 0.950; for survival: sensitivity = 19/20 = 0.950]. For the Discovery Study, the rOC AUC of the F1 is 0.98929 with a 95% 
CI = [0.90449, 0.99884]. The mean F1 score of the 14 r/LTS subjects was 17.9358 (top of green bar) and the standard deviation (whisker above or below 
the top of the green bar) was 2.9622; whereas the mean F1 score of the 20 Nr/STS subjects was 25.4697 (top of purple bar) and the standard deviation 
(whisker above or below the top of the purple bar) was 3.3651. The significance level was set at α = 0.001 (two-tailed), and the probability of significance 
was P = 1.30 × 10–7 (independent t-Test with T-value = −6.7405). The F1 is parametrically distributed with respect to both groups. (B) Scatter plot and bar 
graph of all 34 original subjects (14 r/LTS and 20 Nr/STS) used in the Discovery Study in connection with the F2 and F3 prognostic biomarker models. As 
can be seen, 13/14 r/LTS subjects (green color) had F2 scores less than the determined cut-off score of 14.3, and, therefore, 13/14 subjects were identi-
fied correctly [for treatment response: sensitivity = 13/14 = 0.929; for survival: specificity = 13/14 = 0.929]. regarding the Nr/STS group (purple color), 
all 20 subjects had F2 scores greater than the determined cut-off score of 14.3, and, therefore, they were all identified correctly [for treatment response: 
specificity = 1.000; for survival: sensitivity = 1.000]. As can also be seen, all 14 r/LTS subjects (green color) had F3 scores less than the determined cut-off 
score of 14.7, and, therefore, they were all identified correctly [for treatment response: sensitivity = 1.000; for survival: specificity = 1.000]. regarding the 
Nr/STS group (purple color), 19/20 subjects had F3 scores greater than the determined cut-off score of 14.7, and, therefore, 19/20 subjects were identi-
fied correctly [for treatment response: specificity = 19/20 = 0.950; for survival: sensitivity = 19/20 = 0.950]. For the Discovery Study, the rOC AUC of the 
F2 is 0.98929 with a 95% CI = [ 0.90321, 0.99886 ], whereas the ROC AUC of the F3 is 0.98214 with a 95% CI = [0.86165, 0.99782]. The mean F2 score of 
the 14 r/LTS subjects was 13.4223 (top of green bar) and the standard deviation (whisker above or below the top of the green bar) was 0.8905; whereas 
the mean F2 score of the 20 Nr/STS subjects was 15.1843 (top of purple bar) and the standard deviation (whisker above or below the top of the purple 
bar) was 0.6407. The mean F3 score of the 14 r/LTS subjects was 13.8864 and the standard deviation was 0.7017; whereas the mean F3 score of the 
20 NR/STS subjects was 15.3433 and the standard deviation was 0.6082. The significance level was set at α = 0.001 (two-tailed), and the probability of 
significance for the F2 was P = 1.37 × 10–7 (independent t-Test with T-value = −6.7217), whereas the probability of significance for the F3 was P = 2.93 × 10–7 
(independent t-Test with T-value = −6.4541). Both the F2 and the F3 are parametrically distributed with respect to both groups.
The EED protein is part of the Polycomb-group 
(PcG)  proteins  involved  in  repressive  transcrip-
tional control28 mediated via histone deacetylation.29 
We  found  that  the  EED  gene  was  significantly 
under-expressed  in  the  NR/STS  group  relative  to 
the R/LTS group, indicating that in the case of more 
aggressive EOC, inhibitory control of gene activity 
was more diminished.
USP5 belongs to the largest class of deubiquitinat-
ing  enzymes  (USPs)  that  regulate  protein  ubiquit-
ination,  a  post-translational  modificationof  cellular 
proteins.  Compounds  that  inhibit  the  regulation  of 
protein ubiquitination, such as bortezomib, have been 
approved by the FDA and are used for the treatment of 
certain types of cancer.30,31 Moreover, other compounds 
that specifically suppress the activity of USP5, such 
as WP1130, lead to apoptosis of tumor cells.32 Those 
findings are in agreement with our results: we found 
that the USP5 gene was significantly over-expressed 
in the NR/STS group relative to the R/LTS group. 
There is also evidence that malignant tumors, via the 
release of certain factors, may promote the expres-
sion of USPs and other deubiquitinating enzymes in 
order to induce major alterations in the metabolism, 
such as increased proteolysis and lipolysis, for energy 
purposes.33,34
The  third  group  comprises  genes  whose  func-
tion is involved in metabolism in general and lipid Prognosis of treatment response and survival in ovarian cancer
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Figure 2.  3D Scatter plot of all 34 original subjects [14 R/LTS (green) 
and 20 Nr/STS (purple)] used in the Discovery Study in connection with 
the F1, F2, and F3 prognostic biomarker models. The F1, F2, and F3 scores 
of all 34 original subjects are plotted against each other (F1 vs. F2 vs. F3). 
As can be seen, there are two distinct, separate clusters: the green one 
(r/LTS group) is at the front and at a lower level, whereas the purple one 
(Nr/STS group) is at the back and at a higher level. It can also be seen 
that one subject from the NR/STS group was misclassified.
metabolism in particular. Those genes are: LYPLA2, 
OSBPL8, HLCS, and NDUFB1.
Throughout all its stages, carcinogenesis entails 
extensive remodeling of lipid metabolism. In many 
different  types  of  cancer,  altered  lipid  metabolism 
has been observed.35,36 Owing to increased demand 
for membrane biosynthesis and energy for the gen-
eration and sustenance of new cells, carcinogenesis 
effects alterations not only in lipid metabolism but 
also in glycolysis,37,38 with the most drastic altera-
tions observed in the most aggressive tumor cells.35 
LYPLA2 is the enzyme that catalyzes the hydroly-
sis of 2-lysophosphatidylcholine (which, along with 
arachidonic acid, is derived from the hydrolysis of 
phosphatidylcholine—a phospholipid that is a major 
component of cell membranes) to glycerophospho-
choline. As was mentioned above, there is evidence 
that malignant tumors produce certain factors, such 
as PIF, which promote cell survival under hypoxia 
and oxidative stress by altering metabolism so that 
energy  can  be  derived  from  both  proteolysis  and 
lipolysis.33,34  More  specifically,  PIF  induces  prote-
olysis by increasing the expression of deubiquitinat-
ing  enzymes,  such  as  USPs—a  process  mediated 
by the conversion of arachidonic acid to 15-HETE 
(15-hydroxyeicosatetraenoic acid).39 Moreover, both 
of  the  aforementioned  hydrolytic  reactions  result 
in the release of fatty acids, which may be utilized 
for energy production via β-oxidation. Cachexia, a 
condition  characterized  by  progressive  body  mass 
loss due to extensive proteolysis and lipolysis, has 
been observed in connection with cancer, and it has 
been associated with a poor survival rate, a dimin-
ished chemotherapy response, and an increased tox-
icity  intolerance.33  According  to  our  analysis,  the 
LYPLA2  gene  was  significantly  over-expressed  in 
the NR/STS group relative to the R/LTS group; that 
accords with the aforementioned observations and, 
along  with  the  significant  over-expression  of  the 
USP5 gene, suggests greater protein and lipid catabo-
lism for energy purposes (via β-oxidation) on the part 
of the more aggressive cancer cells (NR/STS group).
The  protein  OSBPL8  is  an  intracellular  lipid 
receptor that belongs to the family of oxysterols (oxy-
genated cholesterol derivatives). Oxysterols activate 
the liver X receptors (LXR) that regulate the expres-
sion of a number of genes whose function pertains 
to  cholesterol  metabolism.40  Some  of  those  genes, 
such as SREBP1, have been shown to promote fatty 
acid synthesis when activated by the oxysterol/LXR 
group.41,42 We found that the OSBPL8 gene was sig-
nificantly under-expressed in the NR/STS group rela-
tive to the R/LTS group, suggesting that lipogenesis is 
more suppressed in the more aggressive cancer cells. 
That is in agreement with our findings about the over-
expression of the LYPLA2 gene in the same group 
(NR/STS), which points to a greater lipolysis in the 
case of the more aggressive cancer cells.
HLCS is an enzyme that catalyzes the covalent 
biotinylation  of  the  five  crucial  mammalian  car-
boxylase  enzymes:  pyruvate  carboxylase  (PC), 
acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2), 
3-methylcrotonyl-CoA carboxylase (MCC), and pro-
pionyl-CoA carboxylase (PCC). From an energy pro-
duction perspective, the most likely targets of HLCS 
in connection with advanced-stage EOC are PCC and 
MCC. The former catalyzes the carboxylation of pro-
pionyl CoA, which is the end product of the metabo-
lism of the fatty acids with an odd number of carbons, 
and which, at the end of β-oxidation, is converted into 
succinyl-CoA, which then can enter the TCA cycle. 
MCC is a key enzyme in the breakdown of leucine, Nikas et al
242  Cancer Informatics 2011:10
which is eventually broken down to acetoacetate and 
acetyl CoA, the latter of which can enter the TCA 
cycle. High demand for energy, however, would serve 
no purpose if it were the only requirement on the 
part of cancer cells; it is matched by an equally high 
demand  for  materials  necessary  for  the  generation 
of new cells—materials such as cytostructural pro-
teins (tubulin, actin, etc.), which require biosynthesis 
of amino acids. The TCA cycle can be used for the 
biosynthesis of non-essential amino acids provided 
it is anaplerotically sustained, something which can 
be accomplished via the end products of the afore-
mentioned PCC and MCC, or via the aforementioned 
pyruvate carboxylase (PC) [conversion of pyruvate to 
oxaloacetate], or via glutaminolysis [breaking down 
glutamine into α-ketoglutarate]. All those metabolic 
processes and pathways are regulated by the HLCS 
gene, something that signifies its immense importance 
not only in cancer but also in health. We found that 
the HLCS gene was significantly over-expressed in 
the NR/STS group relative to the R/LTS group, which 
suggests higher lipolysis and proteolysis in the case 
of the more aggressive cancer cells, and which is in 
accordance with our findings on the previous genes.
Along with 45 other subunits, the NDUFB1dehy-
drogenase (ubiquinone) 1 beta subcomplex constitutes 
the mitochondrial Complex I—a very large multipro-
tein enzyme which is located in the inner mitochondrial 
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Figure 3. (A) Scatter plot and bar graph of all 20 unknown (new and different) subjects [10 R/LTS (green) and 10 NR/STS (purple)] used in the Validation 
Study in connection with the F1 prognostic biomarker model. As can be seen, all 10 r/LTS subjects (green color) had F1 scores less than the determined 
cut-off score of 21.4, and, therefore, they were all identified correctly [for treatment response: sensitivity = 1.000; for survival: specificity = 1.000]. regard-
ing the Nr/STS group (purple color), all 10 of them had F1 scores greater than the determined cut-off score of 21.4, and, therefore, they were all identified 
correctly [for treatment response: specificity = 1.000; for survival: sensitivity = 1.000]. For the Validation Study, the rOC AUC of the F1 is 1.000. The mean 
F1 score of the 10 r/LTS subjects was 16.1301 (top of green bar) and the standard deviation (whisker above or below the top of the green bar) was 2.9288; 
whereas the mean F1 score of the 10 Nr/STS subjects was 24.3990 (top of purple bar) and the standard deviation (whisker above or below the top of 
the purple bar) was 1.5847. The significance level was set at α = 0.001 (two-tailed), and the probability of significance was P = 3.19 × 10–7 (independent 
t-Test with T-value = −7.8523). The F1 is parametrically distributed with respect to both groups. (B) Scatter plot and bar graph of all 20 unknown (new 
and different) subjects (10 r/LTS and 10 Nr/STS) used in the Validation Study in connection with the F2 and F3 prognostic biomarker models. As can be 
seen, all 10 r/LTS subjects (green color) had F2 scores less than the determined cut-off score of 14.3, and, therefore, they were all identified correctly 
[for treatment response: sensitivity = 1.000; for survival: specificity = 1.000]. regarding the Nr/STS group (purple color), all 10 of them had F2 scores 
greater than the determined cut-off score of 14.3,and, therefore, they were all identified correctly [for treatment response: specificity = 1.000; for survival: 
sensitivity = 1.000]. As can also be seen, all 10 r/LTS subjects (green color) had F3 scores less than the determined cut-off score of 14.7, and, therefore, 
they were all identified correctly [for treatment response: sensitivity = 1.000; for survival: specificity = 1.000]. regarding the Nr/STS group (purple color), 
all 10 of them had F3 scores greater than the determined cut-off score of 14.7,and, therefore, they were all identified correctly [for treatment response: 
specificity = 1.000; for survival: sensitivity = 1.000]. For the Validation Study, therefore, the rOC AUC of both F2and F3 is 1.000. The mean F2 score of the 
10 r/LTS subjects was 13.0048 (top of green bar) and the standard deviation (whisker above or below the top of the green bar) was 0.7932; whereas the 
mean F2 score of the 10 Nr/STS subjects was 14.9212 (top of purple bar) and the standard deviation (whisker above or below the top of the purple bar) 
was 0.3933. The mean F3 score of the 10 r/LTS subjects was 13.6150 and the standard deviation was 0.6979; whereas the mean F3 score of the 10 Nr/
STS subjects was 15.0952 and the standard deviation was 0.2552. The significance level was set at α = 0.001 (two-tailed), and the probability of signifi-
cance for the F2 was P = 2.09 × 10–6 (independent t-Test with T-value = −6.8447), whereas the probability of significance for the F3 was P = 6.14 × 10–6 
(independent t-Test with T-value = −6.2992). Both the F2 and the F3 are parametrically distributed with respect to both groups.Prognosis of treatment response and survival in ovarian cancer
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Table 2. Statistical results of the three prognostic biomarker models (F1, F2, and F3)with respect to both treatment 
response and survival in the Discovery Study (identification of the 34 original subjects) and in the Validation Study (iden-
tification of the 20unknown subjects, which were new and different from the 34 original subjects). (A) The rOC AUC 
value, the 95% confidence interval of the ROC AUC value, the T value and probability of significance of the indepen-
dent t-Test, the 99.99% confidence interval for the mean score of the R/LTS group and that of theNR/STS group, along 
with their respective standard deviations, of the F1, F2, and F3 prognostic biomarker models in the Discovery Study are 
shown. (B) The sensitivity and the specificity of the F1, F2, and F3 prognostic biomarker models in the Discovery Study 
with respect to both treatment response and survival are shown. (c) The rOC AUC value, the sensitivity, and the speci-
ficity of the F1, F2, and F3prognostic biomarker models in the Validation Study with respect to both treatment response 
and survival are shown. (D) The T value and probability of significance of the independent t-Test and the mean score 
of the r/LTS group and that of theNr/STS group, along with their respective standard deviations, of the F1, F2, and F3 
prognostic biomarker models in the Validation Study are shown. As can be seen, all six of those group mean scores, as 
observed in the validation study with the 20 unknown subjects, fall within the 99.99% confidence intervals of the respec-
tive group mean scores as predicted in the discovery study (A).
A (Discovery study)
prognostic 
test
ROc AUc 95% cI of AUc T-Value p 
(2-tailed) 
α = 0.001
R/LTs Group 
[99.99% cI of mean] 
(sD)
nR/sTs Group 
[99.99% cI of mean] 
(sD)
F1 0.98929 [0.90449, 0.99884] −6.7405 1.30 × 10–7 [15.8665, 20.6631] 
(2.9622)
[22.9236, 27.6717] 
(3.3651)
F2 0.98929 [0.90321, 0.99886] −6.7217 1.37 × 10–7 [12.7822, 14.2173] 
(0.8905)
[14.6982, 15.6030] 
(0.6407)
F3 0.98214 [0.86165, 0.99782] −6.4541 2.93 × 10–7 [13.3940, 14.5352] 
(0.7017)
[14.8956, 15.7599] 
(0.6082)
B (Discovery study)
prognostic 
test
ROc AUc sensitivity Specificity
Treatment response survival Treatment response survival
F1 0.98929 1.0000 0.9500 0.9500 1.0000
F2 0.98929 0.9286 1.0000 1.0000 0.9286
F3 0.98214 1.0000 0.9500 0.9500 1.0000
c (Validation study)
prognostic 
test
ROc AUc sensitivity Specificity
Treatment response survival Treatment response survival
F1 1.00000 1.0000 1.0000 1.0000 1.0000
F2 1.00000 1.0000 1.0000 1.0000 1.0000
F3 1.00000 1.0000 1.0000 1.0000 1.0000
D (Validation study)
prognostic 
test
T-Value p 
(2-tailed) 
α = 0.001
R/LTs group 
Mean ± sD
nR/sTs group 
Mean ± sD
F1 −7.8523 3.19 × 10–7 16.1301 ± 2.9288 24.3990 ± 1.5847
F2 −6.8447 2.09 × 10–6 13.0048 ± 0.7932 14.9212 ± 0.3933
F3 −6.2992 6.14 × 10–6 13.6150 ± 0.6979 15.0952 ± 0.2552Nikas et al
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membrane, and which catalyzes the first step of the 
electron  transport  chain,  the  redox  machinery  of 
the oxidative phosphorylation. It has been observed 
by multiple studies43 that, owing to their surround-
ing hypoxic environment, tumor cells rely to a much 
larger  extent  on  anaerobic  glycolysis  to  produce 
energy rather than on oxidative phosphorylation. This 
is in complete agreement with our finding that the 
NDUFB1 gene was significantly under-expressed in 
the NR/STS group relative to the R/LTS group, for it 
points to a lower utilization of oxidative phosphoryla-
tion on the part of the more aggressive cancer cells.
genes related to the mechanism 
of action of taxol
Taxol is an anti-tubulin chemotherapeutic agent that 
acts as a mitotic inhibitor. More specifically, it increases 
polymerization of microtubules from α-β tubulin het-
erodimers, and it stabilizes microtubules by prevent-
ing their depolymerization. This action prevents the 
formation of the mitotic spindle, a necessary step in 
the process of mitosis, and that results in the arrest 
of the mitosis cycle either in the G2 or the M phase.44 
How some cancer cells can evade the action of taxol 
is not clear.45 Over-expressing tubulin, so as to offset 
the action of taxol, may be one way according to our 
evidence.  As was mentioned earlier, the gene TUBA3C, 
which encodes the production of α-tubulin, and which 
is common to all three super variables and one of the 
top four most significant predictors, was significantly 
over-expressed in those patients (NR/STS) who did 
not respond to taxol (platinum/taxol chemotherapy). 
Furthermore, the fact that taxol binds to the β-tubulin 
subunit46,47  would  render  the  over-expression  of 
TUBA3C on the part of the more aggressive cancer 
cells a successful strategy for evading the action of 
taxol and, thus, for survival.
Actin, a globular protein, is the monomeric com-
ponent of microfilaments (part of the cytoskeleton)
and thin filaments (part of the myofibril). β-Actin, 
the monomeric component of microfilaments only, 
belongs to one of the three groups of isoforms of actin 
(α, β, and γ). The β and γ isoforms compose the actin 
cytoskeleton  (microfilament  networks).  The  actin 
cytoskeleton is involved, among other important cel-
lular processes, in regulation of gene transcription, 
chromatin remodeling, cell cytokinesis and mitosis, 
and cell motility.48 That, therefore, cytoskeletal actin, 
β-actin  in  particular,  has  been  linked  to  numerous 
types of cancer should be not surprising. Moreover, 
cytoskeletal actin has been shown to play a role in the 
control of the polarity of the mitotic spindle (microtu-
bule polarization).49 Taxol, on the other hand, besides 
inhibiting  the  depolymerization  of  microtubules, 
has been shown to induce multipolar formation of 
the mitotic spindle,47 preventing thus the organized 
movement  of  the  microtubules,  necessary  for  the 
separation of the chromosomes. Over-expression of 
β-actin could overcome this action of taxol, and that 
is something to which our evidence points: we found 
that the ACTB gene, which encodes for the produc-
tion of β-actin, was significantly over-expressed in 
the NR/STS group relative to the R/LTS group.
The CDC42 gene not only promotes the polym-
erization of actin into microfilaments, the reorgani-
zation of the actin cytoskeleton, and cell formation, 
growth, and spreading; but also it can regulate the 
polarization  of  both  the  actin  and  the  microtubule 
cytoskeleton.  Theoretically,  therefore,  over-expres-
sion of the CDC42 gene can overcome the action of 
taxol, as well; and that is the finding of our analysis: the 
CDC42 gene was significantly over-expressed in the 
NR/STS group relative to the R/LTS group.
R/LTS (n = 10)
NR/STS (n = 10)
Figure 4. 3D Scatter plot of all 20 unknown (new and different) subjects 
[10 R/LTS (green) and 10 NR/STS (purple)] used in the Validation Study 
in connection with the F1, F2, and F3 prognostic biomarker models. The 
F1, F2, and F3 scores of all 20 unknown subjects are plotted against each 
other (F1 vs. F2 vs. F3). As can be seen, there are two distinct, separate 
clusters: the green one (r/LTS group) is at the front and at a lower level, 
whereas the purple one (Nr/STS group) is at the back and at a higher 
level. It can also be seen that there were no misclassifications.Prognosis of treatment response and survival in ovarian cancer
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In  summary,  when  over-expressed,  the  genes 
TUBA3C, ACTB,  and  CDC42  can  collectively  (or 
even perhaps in a given combination thereof) over-
come the exerted actions of taxol and diminish its effi-
cacy. It stands to reason, therefore, to expect that a new 
pharmacological approach whereby, via a combination 
of chemotherapeutic agents, all three of those afore-
mentioned genes are targeted will be more successful 
than the current standard treatment in extending the 
life span of those women with EOC who, because of 
the specific pattern of the aforementioned genetic net-
works, will not respond to the platinum/taxol chemo-
therapy and will turn out to be short-term survivors.
Discussion
Studies in ovarian cancer or cancer in general, for that 
matter, typically culminate with the presentation of 
a list of significantly differentially expressed genes.   
To the best of our knowledge, we are not aware of any 
studies in this field that developed actual prognostic 
tests that could be utilized in the clinic, much less of 
any studies that developed such tests and validated 
them with real, unknown (new and different) subjects 
and demonstrated such high sensitivity and specific-
ity for those tests.
Comparing our results pertaining to the most sig-
nificant genes responsible for determining long-term 
vs. short-term survival in patients with advanced stage 
EOC with those of the original study by Berchuck 
et al7 we noticed that three of our 12 most significant 
genes (Table 1), namely SSR1, PKP4, and EED, were 
also determined to be significant and under-expressed 
in the short-term survivors relative to the long-term 
survivors.We should also point out here that Berchuck 
et al7 used completely different methods from ours 
for their analysis. They employed statistical methods; 
more specifically, they used a combination of a Bayes-
ian classification tree with multivariate discriminant 
analysis. We, on the other hand, performed mathemat-
ical modeling to generate functions that can describe 
the process of interest as accurately as possible.
Having  utilized  our  novel  mathematical  theory 
and bioinformatic approach, we were able to 1) iden-
tify a group of most significant genes and 2) gener-
ate three complex mathematical functions that can 
prognose  with  a  high  degree  of  accuracy  the  out-
come of treatment response and survival in patients 
with late stages of EOC at the earliest possible time 
(diagnosis/surgery).  Following  validation  with  20 
unknown  (new  and  different)  subjects,  and  with 
respect to both treatment response and survival, our 
three prognostic biomarker models exhibited an over-
all sensitivity from 95.83% to 100% and an overall 
specificity also from 95.83% to 100%. Provided there 
is further and more extensive validation, the clinical 
significance of our three prognostic biomarker mod-
els is evident: physicians will be able to identify from 
the outset those EOC patients who will and will not 
respond to the platinum/taxol chemotherapy, and they 
will consequently administer a different treatment to 
the latter. This could result in a considerable increase 
of the survival of those patients who do not respond 
to the conventional treatment.
Pertaining  to  the  genetic  networks  that  cause  a 
discrimination between the NR/STS and the R/LTS 
patients  with  EOC,  our  findings  on  the  12  genes 
employed by the three prognostic biomarker mod-
els can be summarized as follows: compared with 
the R/LTS group, the NR/STS group exhibited a sig-
nificant  increase  in  1)  generation  of  cytostructural 
proteins, 2) cell proliferation, and 3) cell energy pro-
duction (via a significant increase in anaerobic gly-
colysis,  lipolysis,  and  proteolysis).  Given  that  our 
three prognostic biomarker models (complex math-
ematical functions), by utilizing the aforementioned 
12  genes  as  input  variables,  can  identify  the  NR/
STS and the R/LTS patients with EOC with a high 
accuracy, it follows that those 12 genes, which com-
pose three distinct genetic networks, are responsible 
for determining both the treatment-response and the 
survival outcome in patients with late stage EOC. 
The fact that the patient tumor tissue was collected 
during surgery, and that all patients received chemo-
therapy only after surgery, further reinforces the pre-
vious statement, ie, that the genetic patterns of the 
aforementioned 12 genes as generated by our three 
prognostic biomarker models can determine a priori 
whether a patient with advanced stage EOC will be 
a responder to the platinum/taxol chemotherapy (and 
therefore a long-term survivor) or otherwise. This in 
conjunction with the fact that one of the genetic net-
works, namely, TUBA3C, ACTB, and CDC42, could 
be influenced by anti-tubulin agents, such as taxanes 
and  epothilones,  could  have  significant  pharmaco-
logical implications for the treatment of EOC in the 
future. For example, those EOC patients who, after Nikas et al
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surgery, are prognosed to be non-responders (short-
term survivors) could be treated with a combination 
of the aforementioned anti-tubulin agents or with new 
anti-tubulin agents or with other chemotherapeutic 
agents and be monitored for a successful outcome, ie, 
for a survival period greater than 3 years. Moreover, 
the  same  investigative  pharmacological  approach 
could be applied by using a different family of che-
motherapeutic agents and targeting any or both of the 
other  two  gene  networks  (cell  proliferation  and/or 
cell energy production). As was mentioned earlier, a 
pharmacological approach that could target all three 
gene networks at the same time may turn out to be 
the most successful.
In the end, utilizing our prognostic biomarker tests 
for the development of new, more effective pharma-
cological regimens may lead to considerably more 
successful treatments, ie, to a significant increase in 
the survival of all patients with advanced stage EOC.
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